Targeting human B-cell malignancies through Ig light chain-specific cytotoxic T lymphocytes

Clinical Cancer Research

Volumn 17, Issue 18, 2011, Pages 5945-5952

  Weng, Jinsheng ^a   Cha, Soung Chul ^a   Matsueda, Satoko ^b   Alatrash, Gheath ^a   Popescu, Michael S ^a   Yi, Qing ^a   Molldrem, Jeffrey J ^a   Wang, Michael ^a   Neelapu, Sattva S ^a   Kwak, Larry W ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; HLA A ANTIGEN; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; PEPTIDE DERIVATIVE;

AMINO ACID SEQUENCE; ARTICLE; CHRONIC LYMPHATIC LEUKEMIA; COCULTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; FOLLICULAR LYMPHOMA; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN CELL; IMMUNOGENICITY; MYELOMA CELL; PLASMA CELL LEUKEMIA; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

ANTIGENS, NEOPLASM; CELL LINE, TUMOR; EPITOPES; EPITOPES, T-LYMPHOCYTE; HUMANS; IMMUNOGLOBULIN IDIOTYPES; IMMUNOGLOBULIN LIGHT CHAINS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MULTIPLE MYELOMA; PEPTIDES; T-LYMPHOCYTES, CYTOTOXIC; TISSUE DONORS;

EID: 80052845092     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-0970     Document Type: Article

References (37)

1. Lynch RG, Graff RJ, Sirisinha S, Simms ES, Eisen HN. Myeloma proteins as tumor-specific transplantation antigens. Proc Natl Acad Sci U S A 1972;69:1540-4.
2. Kwak LW. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N Engl J Med 1992;327:1209-15.
3. Bendandi M, Gocke CD, Kobrin CB, Benko FA, Sternas LA, Pennington R, et al. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat Med 1999;5:1171-7. (Pubitemid 29474422)
4. Neelapu SS, Kwak LW, Kobrin CB, Reynolds CW, Janik JE, Dunleavy K, et al. Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma. Nat Med 2005;11:986-91. (Pubitemid 41294445)
5. + T cells. Blood 2000;96:2828-33.
6. Schuster SJ, Neelapu SS, Gause BL, Janik JE, Muggia FM, Gockerman JP, et al. Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma. J Clin Oncol 2011;29:2787-94.
7. Giaccone L, Storer B, Patriarca F, Rotta M, Sorasio R, Allione B, et al. Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma. Blood 2011;117:6721-7.
8. Maloney DG, Molina AJ, Sahebi F, Stockerl-Goldstein KE, Sandmaier BM, Bensinger W, et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood 2003;102:3447-54. (Pubitemid 37314788)
9. Lokhorst HM, Schattenberg A, Cornelissen JJ, van Oers MH, Fibbe W, Russell I, et al. Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome. J Clin Oncol 2000;18:3031-7. (Pubitemid 30648798)
10. Kwak LW. Transfer of myeloma idiotype-specific immunity from an actively immunized marrow donor. Lancet 1995;345:1016-20.
11. Neelapu SS, Munshi NC, Jagannath S, Watson TM, Pennington R, Reynolds C, et al. Tumor antigen immunization of sibling stem cell transplant donors in multiple myeloma. Bone Marrow Transplant 2005;36:315-23. (Pubitemid 41195164)
12. Tiller T, Meffre E, Yurasov S, Tsuiji M, Nussenzweig MC, Wardemann H. Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning. J Immunol Methods 2008;329:112-24. (Pubitemid 350235462)
13. Nijman HW, Houbiers JG, Vierboom MP, van der Burg SH, Drijfhout JW, D'Amaro J, et al. Identification of peptide sequences that potentially trigger HLA-A2.1-restricted cytotoxic T lymphocytes. Eur J Immunol 1993;23:1215-9. (Pubitemid 23165680)
14. Hida N, Maeda Y, Katagiri K, Takasu H, Harada M, Itoh K. A simple culture protocol to detect peptide-specific cytotoxic T lymphocyte precursors in the circulation. Cancer Immunol Immunother 2002;51:219-28. (Pubitemid 34493956)
15. Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. N Engl J Med 1988;319:1676-80. (Pubitemid 19015247)
16. Pavelko KD, Hansen MJ, Pease LR. CTL activation using the natural low-affinity epitope 222-229 from tyrosinase-related protein 1 leads to tumor rejection. Cancer Res 2009;69:3114-20.
17. Kwak LW, Young HA, Pennington RW, Weeks SD. Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response. Proc Natl Acad Sci U S A 1996;93:10972-7. (Pubitemid 26333102)
18. Neelapu SS, Lee S-T, Qin H, Cha S-C, Woo AF, Kwak LW. Therapeutic lymphoma vaccines: importance of T-cell immunity. Expert Rev Vaccines 2006;5:381-94. (Pubitemid 44167159)
19. Strothmeyer AM, Papaioannou D, Duhren-von Minden M, Navarrete M, Zirlik K, Heining-Mikesch K, et al. Comparative analysis of predicted HLA binding of immunoglobulin idiotype sequences indicates T cell-mediated immunosurveillance in follicular lymphoma. Blood 2010;116:1734-6.
20. King CA, Wills MR, Hamblin TJ, Stevenson FK. Idiotypic IgM on a B-cell surface requires processing for recognition by anti-idiotypic T cells. Cell Immunol 1993;147:411-24. (Pubitemid 23113938)
21. Baskar S, Kobrin CB, Kwak LW. Autologous lymphoma vaccines induce human T cell responses against multiple, unique epitopes. J Clin Invest 2004;113:1498-510. (Pubitemid 39071706)
22. Hansson L, Rabbani H, Fagerberg J, Osterborg A, Mellstedt H. T-cell epitopes within the complementarity-determining and framework regions of the tumor-derived immunoglobulin heavy chain in multiple myeloma. Blood 2003;101:4930-6. (Pubitemid 36857756)
23. Trojan A, Schultze JL, Witzens M, Vonderheide RH, Ladetto M, Donovan JW, et al. Immunoglobulin framework-derived peptides function as cytotoxic T-cell epitopes commonly expressed in B-cell malignancies. Nat Med 2000;6:667-72. (Pubitemid 30398790)
24. Curti A, Tosi P, Comoli P, Terragna C, Ferri E, Cellini C, et al. Phase I/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patient-specific tumour idiotype protein or idiotype (VDJ)-derived class I-restricted peptides. Br J Haematol 2007;139:415-24. (Pubitemid 47512192)
25. Dabadghao S, Bergenbrant S, Anton D, He W, Holm G, Yi Q. Antiidiotypic T-cell activation in multiple myeloma induced by M-component fragments presented by dendritic cells. Br J Haematol 1998;100:647-54. (Pubitemid 28126094)
26. Fagerberg J. T-cell-epitope mapping of the idiotypic monoclonal IgG heavy and light chains in multiple myeloma. Int J Cancer 1999;80:671-80. (Pubitemid 29066276)
27. Cohen S, Haimovich J, Hollander N. Dendritic cell-based therapeutic vaccination against myeloma: vaccine formulation determines efficacy against light chain myeloma. J Immunol 2009;182:1667-73.
28. Wen YJ, Ling M, Lim SH. Immunogenicity and cross-reactivity with idiotypic IgA of VH CDR3 peptide in multiple myeloma. Br J Haematol 1998;100:464-8. (Pubitemid 28270480)
29. Jorgensen T, Bogen B, Hannestad K. T helper cells recognize an idiotope located on peptide 88-114/117 of the light chain variable domain of an isologous myeloma protein (315). J Exp Med 1983;158:2183-8. (Pubitemid 14210815)
30. Ramsay AG, Clear AJ, Kelly G, Fatah R, Matthews J, Macdougall F, et al. Follicular lymphoma cells induce T-cell immunological synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy. Blood 2009;114:4713-20.
31. De Groot AS, Moise L, McMurry JA, Wambre E, Van Overtvelt L, Moingeon P, et al. Activation of natural regulatory T cells by IgG Fc-derived peptide "Tregitopes". Blood 2008;112:3303-11.
32. Inoges S. Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma. J Natl Cancer Inst 2006;98:1292-301. (Pubitemid 44530725)
33. Lum LG, Seigneuret MC, Storb R. The transfer of antigen-specific humoral immunity from marrow donors to marrow recipients. J Clin Immunol 1986;6:389-96. (Pubitemid 17195812)
34. Wimperis JZ, Brenner MK, Prentice HG, Reittie JE, Karayiannis P, Griffiths PD, et al. Transfer of a functioning humoral immune system in transplantation of T-lymphocyte-depleted bone marrow. Lancet 1986;1:339-43. (Pubitemid 16137799)
35. Papadopoulos EB, Ladanyi M, Emanuel D, Mackinnon S, Boulad F, Carabasi MH, et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 1994;330:1185-91. (Pubitemid 24121987)
36. Wen Y-J, Barlogie B, Yi Q. Idiotype-specific cytotoxic T lymphocytes in multiple myeloma: evidence for their capacity to lyse autologous primary tumor cells. Blood 2001;97:1750-5. (Pubitemid 32217243)
37. Wen YJ, Min R, Tricot G, Barlogie B, Yi Q. Tumor lysate-specific cytotoxic T lymphocytes in multiple myeloma: promising effector cells for immunotherapy. Blood 2002;99:3280-5. (Pubitemid 34525308)